Analytical and Bioanalytical Testing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Analytical and Bioanalytical Testing


Pharmaceutical Technology Analytical and Bioanalytical Testing

Analytical method development and testing are crucial for ensuring product quality of pharmaceuticals. This special publication, delivered in electronic format, offers case-study analysis of the chromatographic, spectroscopic, and imaging methods used in the identification, characterization, and quantification of drug substances, and drug products, as well as impurity analysis.
--The editors of Pharmaceutical Technology

View Pharmaceutical Technology's Analytical and Bioanalytical eBook

Impurity Profiling Using Convergence Chromatography and Mass Spectrometry Convergence Chromatography
Impurity Profiling Using Convergence Chromatography and Mass Spectrometry
Michael D. Jones and Warren Potts
Waters Corp.
Multiple Reaction Monitoring—Mass Spectrometry for Biopharmaceutical Analysis

NMR-MS
Multiple Reaction Monitoring–Mass Spectrometry for Biopharmaceutical Analysis
Rowel Tobias and Cadnel Detchou
Analytical Bio-Chemistry Laboratories

John Anders, Simona Rovetta, Paola Belloni, G-Paolo Rizzardi, and John McEntire
MolMed S.p.A

Identification and Quanttiication of Trace-Level Protein Impurities Protein Impurity Analysis
Identification and Quantification of Trace-Level Protein Impurities
Hongxia (Jessica) Wang, Zhiqi Hao, Yi Zhang, David Horn, and Patrick Bennett
Thermo Fisher Scientific
Simultaneous Quantitative and Qualitative Measurements in Drug-Metabolism Investigations LC-MS/MS
Simultaneous Quantitative and Qualitative Measurements in Drug-Metabolism Investigations
Donald Richards; Bruker UK
Ultra-High-Speed Analysis of Ibuprofen Using HPLC HPLC
Ultra-High-Speed Analysis of Ibuprofen Using HPLC
Kenichiro Tanaka, Akane Kato, Hietoshi Terada, Tadayuki Yamaguchi
Shimadzu Scientific Instruments
Characterization with Atomic Force Microscopy, Topographic, and 3D Raman Imaging Microscopy
Characterization with Atomic Force Microscopy, Topographic, and 3D Raman Imaging
Olfa Hollricher, Ute Schmidt, and Harald Fischer
WiTec GmbH

 

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here